Zulfidin 500 mg

Tablet

Pack Size : 10 Tablet x 1 strip

Generics : Sulfasalazine

Manufacturer : Unimed & Unihealth Manufacturers Ltd.

Best Price * TK 70.00

* Delivery will be done in Dhaka city only.

Alternative Product

Tablet Salazine - 500mg Opsonin Pharma Ltd.

Tk 5.23

Tablet Reumazin - 500 MG Aristopharma Limited

Tk 5.20

Tablet Reversair - 10 MG ACI Limited

Tk 17.50

More Information About - Zulfidin 500 mg

Description

Generic Name

Sulfasalazine

Precaution

Hepatic/renal impairment, G6PD deficiency, allergic bronchial asthma, lactation. Lactation: Excreted into human breast milk; caution with breastfeeding, some reports of bloody stools or diarrhea in human milk fed infants of mothers taking sulfasalazine

Indication

Inflammatory bowel disease, Rheumatoid arthritis

Contra Indication

Hypersensitivity to sulphonamides or salicylates, porphyria, <2 yr of age, intestinal or urinary obstruction, blood dycrasias, history of leucopenia with gold therapy.

Dose

N/A

Side Effect

>10% Anorexia (~33%),Headache (~33%),Nausea (~33%),Vomiting (~33%),Gastric distress (~33%),Apparently reversible oligospermia (~33%) <1% Skin rash,Pruritus,Urticaria,Fever,Heinz body anemia,Hemolytic anemia,Cyanosis Potentially Fatal: Severe hypersensitivity reactions, blood dyscrasias, renal and hepatic toxicity, fibrosing alveolitis.

Pregnancy Category

Name : B

Description

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.

Mode of Action

Actual mechanism not determined. Sulphasalazine may have direct anti-inflammatory action in the colon. It also systemically interferes with secretion by prostaglandin synthesis inhibition.

Interaction

Plasma levels reduced by rifampicin and ethambutol. Interferes with absorption of folic acid. Additive leucopaenia with gold therapy for rheumatoid arthritis. Increased haematological toxicity with azathioprine. Reduced serum levels of digoxin.

Pregnancy Category Note

Pregnancy category: B; D if used for prolonged periods or near term; increased potential for kernicterus in the newborn Oral sulfasalazine inhibits the absorption and metabolism of folic acid which may interfere with folic acid supplementation and protection from neural tube defects Lactation: Excreted into human breast milk; caution with breastfeeding, some reports of bloody stools or diarrhea in human milk fed infants of mothers taking sulfasalazine

Adult Dose

Oral Inflammatory bowel disease Adult: Initially, 1-2 g 4 times daily until remission occurs. Maintenance: 2 g/day in divided doses. Rheumatoid arthritis Adult: As enteric-coated tablet: Initially, 500 mg daily for the 1st wk increased by 500 mg every wk. Max: 3 g daily in 2-4 divided doses. Rectal Inflammatory bowel disease Adult: As suppository: 0.5-1 g in the morning and night, either alone or as an adjunct to oral treatment. Hepatic impairment: Avoid use.

Child Dose

Oral Inflammatory bowel disease Child: >2 yr: 40-60 mg/kg/day in divided doses. Maintenance: 20-30 mg/kg/day in divided doses. Rheumatoid arthritis Child: For polyarticular juvenile rheumatoid arthritis: >6 yr: As enteric-coated tablet: 30-50 mg/kg/day in 2 divided doses. Begin treatment with 1/4 to 2/3 of expected maintenance dose and increase wkly to reach maintenance dose in 1 mth. Max: 2 g daily. Rectal Inflammatory bowel disease Child: As suppository (may be given as divided doses): 5-8 yr: 500 mg bid; 8-12 yr: 500 mg in the morning and 1 g at night; 12-18 yr: 1 g bid.

Renal Dose

Renal impairment: CrCl (ml/min) Dosage Recommendation 10-30ml/min Admin twice daily. <10ml/min Admin once daily.

Administration

Should be taken with food. Take after meals. Ensure adequate fluid intake.

Disclaimer

The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.